Remimazolam Versus Propofol During Hysteroscopy: A Systematic Review And Meta-Analysis of Nine Randomized Controlled Trials
Clinical Therapeutics
Research outputs
مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.
12 مُخرَج نتائج البحث عن «Randomized controlled trial»
Clinical Therapeutics
European Archives of Psychiatry and Clinical Neuroscience · مجلد 276 (5) · 2727-2737
Orbit · مجلد 45 (3) · 479-487
Purpose Graves’ ophthalmopathy (GO) is an autoimmune orbital inflammatory disease associated with Graves’ disease. It can cause vision loss, facial disfigurement, and reduced quality of life. Systemic corticosteroids remain the first-line treatment for moderate-to-severe GO, administered either orally or intravenously. However, the optimal route of administration remains uncertain, with ongoing debate regarding their comparative efficacy and safety.The aim of this review is to compare the efficacy and safety of intravenous versus oral corticosteroids in the treatment of moderate-to-severe GO.Methods Randomized controlled trials were included. Risk of bias was assessed using the Cochrane RoB 2 tool. Outcomes focused on efficacy and safety of intravenous versus oral glucocorticoids in the treatment of GO.Results Five eligible RCTs involving 288 patients were analyzed. Intravenous steroids appeared to improve the clinical activity score (MD = −0.57; 95% CI: −0.82 to −0.33; p < 0.00001) and reduce the risk of Cushingoid facial features (RR = 0.17; 95% CI: 0.08 to 0.35; p < 0.00001). However, limited efficacy was observed in diplopia, proptosis, and in minimizing other steroid-related adverse events.Conclusion IV steroids were associated with more favourable outcomes and better tolerability than oral steroids in moderate-to-severe GO. Further comprehensive trials are needed to confirm long-term safety and optimize treatment protocols.
The American Journal of Emergency Medicine · مجلد 97 · 175-182
International Journal of Social Psychiatry · مجلد 72 (5) · 1225-1238
Background: Depression is a serious issue in the world, affecting over 350 million people. Although it may present at any age, adolescence to early adulthood is the most common age of onset, and females are affected twice as much as males. Rumination is a specific known risk factor for the onset, severity, prolongation, and relapse of depression. Relapse prevention in recurrent depression is a significant public health problem, and antidepressants are the current first-line treatment approach. Aim: This study aims to evaluate the efficacy of mindfulness-based cognitive therapy in alleviating depressive symptoms, reducing rumination, and preventing relapse among depressive patients. Method: This randomized controlled trial was conducted with 101 population of 101 consisting of adult patients with three or more previous episodes. Participants were randomly assigned to Mindfulness-Based Cognitive Therapy ( n = 50) and Control Group ( n = 51) using randomized sampling. The Mindfulness-Based Cognitive Therapy group received 8-week group training sessions including meditation exercises, psycho-education and group discussions. The assessment was done at baseline, post-treatment, and 2-month follow-up. Analysis was done using SPSS software (V 22). Result: The results showed that there were no significant differences between the groups on depression relapse (χ 2 = 0.002; p = 0.99). However, there is a statistically significant reduction in depressive symptoms mean score level in the MBCT group [ F (2, 37) = 6.878, p = .003]. Moreover, there is a statistically significant reduction in rumination score in the MBCT group [F (2,37) = 36.021; p = 0.02]. Conclusion: The findings showed that MBCT appears efficacious in reducing depressive symptoms and rumination. However, MBCT did not further reduce their risk for relapse/recurrence.
European Heart Journal · مجلد 46 (Supplement_1)
Abstract Purpose Angiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety when initiated in acute decompensation (ADHF) remain less well characterized. This meta-analysis evaluates the efficacy and safety of ARNI compared to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for ADHF. Methods A meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, WOS, Embase, and CENTRAL till November 2024. Risk ratios (RR) were applied for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). Results Three RCTs with 1,741 patients were included. Use of ARNI after stabilization of ADHF resulted in a significant reduction of HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57 to 0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57 to 0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64 to 1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p < 0.0001) or 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI was associated with a higher risk of symptomatic hypotension (RR: 1.33; 95% CI: 1.04 to 1.71; p = 0.024). Conclusion Pooled data demonstrate that the initiation of ARNI post-ADHF can be effective compared with ACEIs/ARBs for both cardiovascular and renal benefits at the expense of increased risk for symptomatic hypotension.
Reproductive Sciences · مجلد 32 (11) · 3525-3538
Journal of Gynecology Obstetrics and Human Reproduction · مجلد 53 (5) · 102770-102770
Circulation · مجلد 150 (Suppl_1)
Background: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. Apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran, reduced triglycerides in the previous trials. However, the safety and efficacy of the three medications have not been compared yet. Methods: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Nine randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. Results: A total of 782 patients were included. Volanesorsen 300 mg once weekly showed the most significant reduction in triglyceride levels (MD = -90.98%, 95% CI: [-109.2%; -72.8%]; p<0.01 ). Only plozasiran once monthly, regardless of the dose, showed a non-significant reduction in triglycerides, which should be taken with caution as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo with plozasiran 100 mg and 50 mg once monthly and volanesorsen 300 mg once weekly, showing the most significant reduction (MD range: -92.8% to -88.4%; p<0.01 ). Plozasiran regimens, especially the 25 mg, 50 mg, and 10 mg once monthly dosages, respectively, reduced total cholesterol levels the most compared to placebo (MD range: -30.6% to -23.5%; p<0.01 ). Only volanesorsen, regardless of the dose, did not significantly reduce total cholesterol compared to placebo. None of the treatments showed a statistically significant difference in the adverse events rate compared to placebo. Conclusion: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride, APOC3, and total cholesterol levels in hypertriglyceridemia, with an acceptable safety profile. However, due to the relatively small sample size, the results should be interpreted with caution. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and provide strong evidence on the effects of each medication regimen.
American Journal of Perinatology · مجلد 41 (S 01) · e2034-e2046
OBJECTIVE: This study aimed to conduct a systematic review and meta-analysis of all randomized and nonrandomized controlled trials (RCTs and NCTs, respectively) that explored the maternal-neonatal outcomes of cervical osmotic dilators versus dinoprostone in promoting cervical ripening during labor induction. STUDY DESIGN: Six major databases were screened until August 27, 2022. The quality of included studies was evaluated. The data were summarized as mean difference or risk ratio (RR) with 95% confidence interval (CI) in a random-effects model. RESULTS: = 0.51). Additionally, there was no significant difference between both groups regarding the mean change in Bishop score and mean time from intervention to delivery. The rate of uterine hyperstimulation was significantly lower in the cervical osmotic dilator group. For the neonatal outcomes, during cervical ripening, the rate of fetal distress was significantly lower in the cervical osmotic dilator group. There was no significant difference between both groups regarding the mean Apgar scores, rate of meconium-stained amniotic fluid, rate of umbilical cord metabolic acidosis, rate of neonatal infection, and rate of neonatal intensive care unit admission. CONCLUSION: During labor induction, cervical ripening with cervical osmotic dilators and dinoprostone had comparable maternal-neonatal outcomes. Cervical osmotic dilators had low risk of uterine hyperstimulation compared with dinoprostone. Overall, cervical osmotic dilators might be more preferred over dinoprostone in view of their analogous cervical ripening effects, comparable maternal-neonatal outcomes, and lack of drug-related adverse events. KEY POINTS: · This is the first analysis of cervical osmotic dilators versus PGE2 for cervical ripening during labor.. · There was no difference between both arms regarding the rates of normal vaginal/cesarean deliveries.. · There was no difference between both arms regarding the rates of neonatal adverse events.. · Cervical osmotic dilators had significant lower risk of uterine hyperstimulation compared with PGE2.. · Cervical osmotic dilators may be superior to PGE2 in view of their similar efficacy and better safety..
European Journal of Obstetrics & Gynecology and Reproductive Biology · مجلد 291 · 61-69
European Journal of Obstetrics & Gynecology and Reproductive Biology · مجلد 276 · 38-46